BioCardia, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
BioCardia, Inc. (BCDA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $71.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-24
- BioCardia, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $71.00K, a 59.66% decline from fiscal 2024.
- BioCardia, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $176.00K, a 1.12% decline from fiscal 2023.
- BioCardia, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $178.00K, a 76.24% increase from fiscal 2022.
- BioCardia, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $101.00K, a 61.74% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $71.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $176.00K 10-K · filed 2026-03-24 |
| 2023-12-31 | $178.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | $101.00K 10-K · filed 2024-03-27 |
| 2021-12-31 | $264.00K 10-K · filed 2023-03-29 |
| 2020-12-31 | $649.00K 10-K · filed 2022-03-29 |
| 2019-12-31 | $446.00K 10-K · filed 2021-03-30 |
| 2018-12-31 | $440.00K 10-K · filed 2020-04-09 |
| 2017-12-31 | $344.00K 10-K · filed 2020-04-09 |
| 2016-12-31 | $136.00K 10-K · filed 2019-04-02 |
| 2015-12-31 | $89.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |